Cargando…

UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer

The development of a colorectal adenoma (CA) into carcinoma (CRC) is a long and stealthy process. There remains a lack of reliable biomarkers to distinguish CA from CRC. To effectively explore underlying molecular mechanisms and identify novel lipid biomarkers promising for early diagnosis of CRC, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hongwei, Zhang, Jiahao, Zhou, Hailin, Zhu, Yifan, Liang, Yunxiao, Zhu, Pingchuan, Zhang, Qisong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366052/
https://www.ncbi.nlm.nih.gov/pubmed/35965551
http://dx.doi.org/10.3389/fonc.2022.934145
_version_ 1784765472276742144
author Chen, Hongwei
Zhang, Jiahao
Zhou, Hailin
Zhu, Yifan
Liang, Yunxiao
Zhu, Pingchuan
Zhang, Qisong
author_facet Chen, Hongwei
Zhang, Jiahao
Zhou, Hailin
Zhu, Yifan
Liang, Yunxiao
Zhu, Pingchuan
Zhang, Qisong
author_sort Chen, Hongwei
collection PubMed
description The development of a colorectal adenoma (CA) into carcinoma (CRC) is a long and stealthy process. There remains a lack of reliable biomarkers to distinguish CA from CRC. To effectively explore underlying molecular mechanisms and identify novel lipid biomarkers promising for early diagnosis of CRC, an ultrahigh-performance liquid chromatography tandem high-resolution mass spectrometry (UHPLC-HRMS) method was employed to comprehensively measure lipid species in human serum samples of patients with CA and CRC. Results showed significant differences in serum lipid profiles between CA and CRC groups, and 85 differential lipid species (P < 0.05 and fold change > 1.50 or < 0.67) were discovered. These significantly altered lipid species were mainly involved in fatty acid (FA), phosphatidylcholine (PC), and triacylglycerol (TAG) metabolism with the constituent ratio > 63.50%. After performance evaluation by the receiver operating characteristic (ROC) curve analysis, seven lipid species were ultimately proposed as potential biomarkers with the area under the curve (AUC) > 0.800. Of particular value, a lipid panel containing docosanamide, SM d36:0, PC 36:1e, and triheptanoin was selected as a composite candidate biomarker with excellent performance (AUC = 0.971), and the highest selected frequency to distinguish patients with CA from patients with CRC based on the support vector machine (SVM) classification model. To our knowledge, this study was the first to undertake a lipidomics profile using serum intended to identify screening lipid biomarkers to discriminate between CA and CRC. The lipid panel could potentially serve as a composite biomarker aiding the early diagnosis of CRC. Metabolic dysregulation of FAs, PCs, and TAGs seems likely involved in malignant transformation of CA, which hopefully will provide new clues to understand its underlying mechanism.
format Online
Article
Text
id pubmed-9366052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93660522022-08-12 UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer Chen, Hongwei Zhang, Jiahao Zhou, Hailin Zhu, Yifan Liang, Yunxiao Zhu, Pingchuan Zhang, Qisong Front Oncol Oncology The development of a colorectal adenoma (CA) into carcinoma (CRC) is a long and stealthy process. There remains a lack of reliable biomarkers to distinguish CA from CRC. To effectively explore underlying molecular mechanisms and identify novel lipid biomarkers promising for early diagnosis of CRC, an ultrahigh-performance liquid chromatography tandem high-resolution mass spectrometry (UHPLC-HRMS) method was employed to comprehensively measure lipid species in human serum samples of patients with CA and CRC. Results showed significant differences in serum lipid profiles between CA and CRC groups, and 85 differential lipid species (P < 0.05 and fold change > 1.50 or < 0.67) were discovered. These significantly altered lipid species were mainly involved in fatty acid (FA), phosphatidylcholine (PC), and triacylglycerol (TAG) metabolism with the constituent ratio > 63.50%. After performance evaluation by the receiver operating characteristic (ROC) curve analysis, seven lipid species were ultimately proposed as potential biomarkers with the area under the curve (AUC) > 0.800. Of particular value, a lipid panel containing docosanamide, SM d36:0, PC 36:1e, and triheptanoin was selected as a composite candidate biomarker with excellent performance (AUC = 0.971), and the highest selected frequency to distinguish patients with CA from patients with CRC based on the support vector machine (SVM) classification model. To our knowledge, this study was the first to undertake a lipidomics profile using serum intended to identify screening lipid biomarkers to discriminate between CA and CRC. The lipid panel could potentially serve as a composite biomarker aiding the early diagnosis of CRC. Metabolic dysregulation of FAs, PCs, and TAGs seems likely involved in malignant transformation of CA, which hopefully will provide new clues to understand its underlying mechanism. Frontiers Media S.A. 2022-07-28 /pmc/articles/PMC9366052/ /pubmed/35965551 http://dx.doi.org/10.3389/fonc.2022.934145 Text en Copyright © 2022 Chen, Zhang, Zhou, Zhu, Liang, Zhu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Hongwei
Zhang, Jiahao
Zhou, Hailin
Zhu, Yifan
Liang, Yunxiao
Zhu, Pingchuan
Zhang, Qisong
UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
title UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
title_full UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
title_fullStr UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
title_full_unstemmed UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
title_short UHPLC-HRMS–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
title_sort uhplc-hrms–based serum lipisdomics reveals novel biomarkers to assist in the discrimination between colorectal adenoma and cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366052/
https://www.ncbi.nlm.nih.gov/pubmed/35965551
http://dx.doi.org/10.3389/fonc.2022.934145
work_keys_str_mv AT chenhongwei uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer
AT zhangjiahao uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer
AT zhouhailin uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer
AT zhuyifan uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer
AT liangyunxiao uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer
AT zhupingchuan uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer
AT zhangqisong uhplchrmsbasedserumlipisdomicsrevealsnovelbiomarkerstoassistinthediscriminationbetweencolorectaladenomaandcancer